LG is/has been supported (as a PI unless otherwise indicated) by one R01 grant from the NIH/NCI (#CA271915), by two Breakthrough Level 2 grants from the US DoD BCRP (#BC180476P1, #BC210945), by a grant from the STARR Cancer Consortium (#I16-0064), by a Transformative Breast Cancer Consortium Grant from the US DoD BCRP (#W81XWH2120034, PI: Formenti), by a U54 grant from NIH/NCI (#CA274291, PI: Deasy, Formenti, Weichselbaum), by the 2019 Laura Ziskin Prize in Translational Research (#ZP-6177, PI:
References (47)M.J. Bissell et al.Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progressionNature Medicine
(2011)
R. BrownPoised epigenetic states and acquired drug resistance in cancerNature Reviews. Cancer
(2014)
G. Cavalli et al.Advances in epigenetics link genetics to the environment and diseaseNature
(2019)
D. DershA few good peptides: MHC class I-based cancer immunosurveillance and immunoevasionNature Reviews. Immunology
(2021)
K.J. Falkenberg et al.Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disordersNature Reviews. Drug Discovery
(2014)
A.P. FeinbergEpigenetic modulators, modifiers and mediators in cancer aetiology and progressionNature Reviews. Genetics
(2016)
M.H. Fitz-James et al.Molecular mechanisms of transgenerational epigenetic inheritanceNature Reviews. Genetics
(2022)
C. Galassi et al.Epigenetic escape of immunosurveillance by malignant cell precursorsThe EMBO Journal
(2023)
L. Galluzzi et al.Immuno-epigenetic escape of cancer stem cellsNature Immunology
(2022)
L. GalluzziImmunological mechanisms underneath the efficacy of cancer therapyCancer Immunol. Res
(2016)
G.J. Goodall et al.RNA in cancerNature Reviews. Cancer
(2021)
D. HanahanHallmarks of cancer: new dimensionsCancer Discov
(2022)
J.G. Herman et al.Gene silencing in cancer in association with promoter hypermethylationThe New England Journal of Medicine
(2003)
View full textCopyright © 2023 Elsevier Inc. All rights reserved.
Comments (0)